It is a fact that has long baffled doctors: Cancer in the small intestine is quite rare, whereas colorectal cancer, found in a smaller neighboring organ, is one of the leading causes of cancer death for people. What is it about the colon that seems to “attract” cancer?
To answer this question, Professor Yinon Ben-Neriah at Hebrew University of Jerusalem (HU)’s Lautenberg Center for Immunology and Cancer Research and his team led by Dr. Eliran Kadosh, found that cancer mutations are not necessarily bad actors. In fact, in certain micro-environments like the gut, these mutations can actually help the body to fight cancer, not spread it. However, if the gut microbiome produces high levels of metabolites, like those found in certain bacteria and antioxidant-rich foods like black tea and hot cocoa, then it acts as a particularly hospitable environment to mutated genes and will accelerate the growth of bowel cancers. Their breakthrough findings were published today in Nature magazine.
Prof. Ben-Neriah and his team kept gut microbiomes in mind as they took a closer look at gastrointestinal cancers, and may have found the reason why only 2% of cancers take root in the small intestine, whereas a whopping 98% of cancers take place in the colon. One major difference between these two organs is their levels of gut bacteria: small intestines contain few, whereas colons contain multitudes. “Scientists are beginning to pay more and more attention to the role gut microbiomes play in our health: both their positive effects and, in this case, their sometimes pernicious role in aiding and abetting disease,” explained Prof. Ben-Neriah.
A little background. TP53 is a gene found in every cell which produces a protein called p53. p53 acts as the cell’s barrier, suppressing genetic mutations in the cell. However, when p53 becomes damaged, it not only no longer protects the cell, but drives cancer, helping tumors spread and grow.
To test their theory that gut flora was at play, the researchers introduced mutated p53 (“cancer-driving”) proteins into the gut. Amazingly, the small intestine reacted by converting the mutated p53 cancer driver back to normal p53, turning into “super-suppressors” that were better at suppressing cancer growth than healthy p53 proteins. However, when mutated p53 was introduced into the colon, they did no switcheroo but stayed true to their driving-cancer nature and promoted the cancerous spread. “We were riveted by what we saw,” recalls Prof. Ben-Neriah. “The gut bacteria had a Jekyll and Hyde effect on the mutated p53 proteins. In the small bowel, they totally switched course and attacked the cancerous cells, whereas in the colon they promoted the cancerous growth.”
To further test their theory that gut flora was a major factor as to why mutated p53 were acting as tumor blockers in the small bowel but tumor accelerants in the colon, the scientists administered antibiotics to kill off the colon’s gut flora. Once they did, the mutated p53 was not able to go on its cancer spree.
What’s in this flora that makes colon cancer spread so quickly? A close analysis identified the culprit: gut flora that produces metabolites, aka “antioxidants,” which are found in high concentrations in foods such as black tea, hot chocolate, nuts, and berries. Tellingly, when the scientists fed biological models an antioxidant-rich diet, their gut flora accelerated p53’s cancer-driver mode. This finding is of particular concern to those patients with a family history of colorectal cancer.
“Scientifically speaking, this is new territory. We were astonished to see the extent to which microbiomes affect cancer mutations—in some cases, entirely changing their nature,” shared Prof. Ben-Neriah. Looking towards the future, those at high risk of colorectal cancer may want to screen their gut-flora more frequently and think twice about the foods they digest, antioxidant, and otherwise.
CITATION: Eliran Kadosh, Irit Snir-Alkalay, Avanthika Venkatachalam, Shahaf May, Audrey Lasry, Ela Elyada, Adar Zinger, Maya Shaham, Gitit Vaalani, Marco Mernberger, Thorsten Stiewe, Eli Pikarsky, Moshe Oren, & Yinon Ben-Neriah. DOI: 10.1038/s41586-020-2541-0
FUNDING: Israel Science Foundation, European Research Council, Israel Cancer Research Fund.